PNIBLOG

Glioblastoma MDNA55 Trial Medicenna

Pacific Neuroscience Institute, the leading enrollment site for the MDNA55 clinical trial for Glioblastoma, is still open and enrolling eligible patients. This innovative phase 2 study is for the minimally invasive convection-enhanced delivery (CED) of a new bioengineered targeted therapeutic, MDNA55, in adults with recurrent or progressive glioblastoma. Read more.